EDSA logo

EDSA Edesa Biotech, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$2.05
-0.01 (-0.49%)

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and …

Market Cap: $19.75Mwww.edesabiotech.com

Price

No data yet.

Social Signal Score

36
5d
—
30d
40
2 mentions
—
60d
33
3 mentions
—
90d
33
3 mentions
—
news: 3

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 2Hold 0Sell 0Strong Sell 0

Revenue

$0.00-100.00%
$0.00$136.8K$273.6K$410.4K
Sep 2016Jun 2026

Analyst Estimates

FY2025
$-1.17
$-1.18–$-1.15
2 analysts
FY2026
$-1.99
$-1.99–$-1.98
2 analysts
FY2027
$-2.07
$-2.59–$-1.54
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Pardeep Nijhawan
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
1.06
Country
CA
Piotroski score
1 / 9 (Weak)
Altman Z-score
-8.61
www.edesabiotech.com